Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Haemonetics (HAE) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Haemonetics (HAE) over the last 17 years, with Q4 2025 value amounting to 19.88%.

  • Haemonetics' EBITDA Margin rose 151300.0% to 19.88% in Q4 2025 from the same period last year, while for Dec 2025 it was 19.05%, marking a year-over-year increase of 103300.0%. This contributed to the annual value of 16.3% for FY2025, which is 37000.0% up from last year.
  • Per Haemonetics' latest filing, its EBITDA Margin stood at 19.88% for Q4 2025, which was up 151300.0% from 17.87% recorded in Q3 2025.
  • Over the past 5 years, Haemonetics' EBITDA Margin peaked at 21.58% during Q1 2025, and registered a low of 9.41% during Q2 2021.
  • For the 5-year period, Haemonetics' EBITDA Margin averaged around 9.58%, with its median value being 9.17% (2022).
  • Per our database at Business Quant, Haemonetics' EBITDA Margin plummeted by -203100bps in 2021 and then surged by 166500bps in 2022.
  • Over the past 5 years, Haemonetics' EBITDA Margin (Quarter) stood at 6.01% in 2021, then surged by 104bps to 12.25% in 2022, then decreased by -4bps to 11.77% in 2023, then plummeted by -60bps to 4.75% in 2024, then skyrocketed by 319bps to 19.88% in 2025.
  • Its EBITDA Margin was 19.88% in Q4 2025, compared to 17.87% in Q3 2025 and 16.76% in Q2 2025.